Introduction
Fibromyalgia syndrome (FMS) is a clinically defined chronic condition characterized by chronic widespread pain, sleep disturbances, cognitive dysfunction and fatigue (Wolfe et al., 2011) . Patients often report high levels of disability and of negative mood (H€ auser et al., 2015a) . Psychological factors play a major role in the predisposition, triggering and perpetuation of FMS ( € Uc ßeyler et al., 2017) . Therefore, psychological therapies may help to reduce key symptoms and improve daily functioning.
Among psychological therapies for FMS, the best evidence available is for face-to-face cognitive behavioural therapies (CBTs) (Bernardy et al., 2018) . CBTs were recommended for FMS management by recent evidence-based guidelines Macfarlane et al., 2017) .
Internet-based cognitive psychological therapies (ICBTs) are a growing area of mental health, because they give the chance to improve accessibility to evidence-based treatments. They are cost effective for a wide range of mental health and somatic disorders (Carlbring et al., 2018) .
Internet-based treatments can be distinguished depending on whether the Internet is used to communicate and/or to deliver information as follows:
(1) Web-based self-help programmes using the Internet as a delivery medium without any contact with a mental health care specialist (MHCS) (unguided), (2) Internet-based guided self-help approaches, in which the presentation of a Web-based self-help programme is combined with regular contact with a MHCS (guided), (3) Internet-based therapies such as email, chat or videoconference-based therapies, in which the Internet is only used for communication purposes with a MHCS (online or e-therapy).
Guided ICBTs are superior to unguided interventions regarding the reduction of symptom severity in some mental disorders (Carlbring et al., 2018) . Systematic reviews demonstrated the efficacy of Internet-based psychological interventions for chronic pain: A Cochrane review (Eccleston et al., 2014) included 15 studies with different chronic pain conditions. For participants with non-headache conditions, Internet-based psychological therapies (IPTs) reduced pain, disability, depression, and anxiety post-treatment and at follow-up with considerable uncertainty around the estimates of effect. The review included one study with FMS-patients. A recent review (Buhrman et al., 2016) analysed 22 studies with Internet-based interventions for different pain conditions (among them two FMS-studies) and found small effect sizes for disability, for pain intensity and for catastrophizing.
Until now, no review analysed Internet-based psychological therapy studies for FMS separately. A recent systematic review on CBTs in FMS excluded Internet-delivered studies and found small effect sizes of face-to face CBTs for disability and depression (Bernardy et al., 2018) . Other important questions in the field of ehealth for FMS had not been covered by systematic reviews, too, e.g. how well guided IPTs compare against traditional face-to-face treatments and how well guided compare against unguided IPTs.
These open questions given, we performed a systematic review on the efficacy, acceptability and safety of IPTs compared to any control groups in FMS patients of any age at the end of treatment and at long-term (at least 6 months) follow-up with special emphasis on comparisons of ICBTs versus traditional face-to-face CBTs and of guided versus unguided IPTs.
Methods
The review was performed according to the PRISMA-statement [Preferred Reporting Items for Systematic Reviews and Meta-Analyses (Moher et al., 2009 ) and the recommendations of the Cochrane Collaboration (Higgins et al., 2017) ].
Protocol
Methods of analysis and inclusion criteria were specified in advance (PROSPERO CRD 42017068669).
2.1.1 Criteria for considering studies for this review 2.1.1.1 Types of participants. We included patients of any age with patients' reports of a diagnosis of FMS established by a physician or by an examination of the investigators using any published, recognized and standardized criteria (Smythe, 1981; Yunus et al., 1981; Wolfe et al., 1990 Wolfe et al., , 2010 Wolfe et al., , 2011 Wolfe et al., , 2016 .
2.1.1.2 Types of interventions. We included studies investigated which treatments that were primarily psychological and included recognizable psychotherapeutic content and were based on an established psychological framework. Included studies had to use an Internet-delivered psychological therapy that was required to be interactive with the user (e.g. respond dynamically based on data input by the user). Included studies had to use a technology capable of delivering a psychological treatment programme via the Internet in the absence of (non-guided), or with adjunctive health care professional involvement (guided), e.g. feedback on homework assignments (less time spend with the patient than in face-to-face therapy), or online therapies (therapist contact that involve real-time [synchronous; e.g. instant messaging, real-time chat, Internet phone, videoconferencing] interactions with patients (same time spend with the patient than in face-to-face therapy; Chakrabarti, 2015; Carlbring et al., 2018) . We also considered therapies that used blended treatments, combining both traditional or online face-to-face contact and a remote component for inclusion in this review.
The treatment therapy needed to be designed to promote pain management, by reducing pain experience, disability, and psychological distress, or adaptive behaviour change, or both. Trials had to include at least one comparator arm.
We excluded these types of studies:
• Therapies delivered face-to-face were included in Bernardy et al. (2018) , and are not included in this review.
• Studies categorized as broader telehealth therapies, where technology was used to facilitate traditional communication and treatment between MHCP and the individual with FMS, but did not deliver the primary psychological therapy itself and did not use the Internet to deliver the therapy (e.g. nonautomated email) were excluded.
2.1.1.3 Types of studies. We accepted an attention control, waiting list control, treatment as usual, no therapy and any other active therapy as controls. In case of multiple control groups, we preferred the following order: attention control, waiting list control, treatment as usual, no therapy, other active non-psychogical therapy, traditional face-to-face psychological therapy. We included studies with a parallel and, cross-over design. We included studies with a cross-over design where (1) separate data from the two periods were reported, or (2) data were presented that excluded a statistically significant carry-over effect, or (3) statistical adjustments were carried out in case of a significant carry-over effect. Trials should report at least one of the outcomes of efficacy as defined below and of acceptability or safety as defined below.
We included studies which were available as a full publication or a report of the RCT in a peerreviewed journal or in a database, had 10 or more participants in each treatment arm for analysis at the end of treatment; had a study duration of 2 weeks and more.
2.1.1.4 Types of outcome measures. When there was more than one measure for an outcome we gave preference to the measure that was most frequently used in previous systematic reviews (Bernardy et al., 2018) . When there was a choice between singleitem and multi-item self report tools, we chose multi-item tools on the basis of inferred increased reliability (Bernardy et al., 2018) .
We analysed outcome measures at final treatment (end of treatment) and at long-term (at least 6 months) follow-up. Follow-ups <6 months were not considered for the analysis of long-term followup. If more than one follow-up after 6 months had been conducted, the results of the final follow-up visit were extracted for analysis.
Primary outcomes
We were particularly interested in defining responder outcomes, that is to say the number of patients with a clinically relevant benefit based on the recommendations of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) (Dworkin et al., 2008) . Thirty percent or more pain relief is defined to be a moderate benefit and 50% or more pain relief to be a substantial benefit in chronic pain studies (Moore et al., 2013) . We used an established dichotomous outcome for improvement of health-related quality of life in FMS trials (Bernardy et al., 2018) . Responder criteria for negative mood and disability have been suggested, too (Dworkin et al., 2008) . These responder criteria require the use of the same measure of the respective outcome. Because we expected that the psychological therapies included into this review will use different scales for negative mood, disability, fatigue and sleep problems, we selected continuous variables as outcomes which do not require the use of the same scale for quantitative analysis.
(1) Pain relief of 50% or greater (dichotomous vari- 
Search methods for identification of studies

Electronic searches
We searched: • SCOPUS (Inception to 20 January 2018
The search strategy for MEDLINE is outlined in Supporting Information Methods S1.
Searching other resources
We searched http://www.clinicaltrials.gov (website of the US National Institutes of Health) for ongoing trials. We searched bibliographies from retrieved relevant articles. We contacted content experts for further possible studies. Our search included all languages.
Measures of treatment effect
The effect measures of choice were risk differences (RD) for dichotomous data and standardized mean difference (SMD) for continuous data (method inverse variance). We used a random-effect model because we assumed clinical heterogeneity between the studies. Uncertainty was expressed using 95% confidence intervals (CIs). Number needed to treat for an additional benefit (NNTBs) was calculated as the reciprocal of the absolute risk reduction (ARR). For unwanted effects, the NNTB becomes the number needed to treat for an additional harm (NNTH) and is calculated in the same manner. For dichotomous data, we calculated RDs. The threshold for 'clinically relevant benefit' or 'clinically relevant harm' was set for categorical variables by an absolute risk reduction or increase ≥10% corresponding a NNTB or NNTH of ≤10 (Moore et al., 2008 ).
Cohen's categories were used to evaluate the magnitude of the effect size of continuous data, calculated by SMD, with values for Hedges' g as follows: 0.2-0.5 equating to a small effect size, 0.5-0.8 equating to a medium effect size, and more than 0.8 equating to a large effect size (Cohen, 1988) . We considered values of g less than 0.2 to equate to a 'not substantial' effect size (H€ auser et al., 2015b) . The threshold 'clinically relevant benefit' was set for continuous variables by an effect size of more than 0.2 (Fayers and Hays, 2014) .
For subgroup analyses, we compared the means and standard deviations if continuous outcomes by unpaired student t-test if the comparison of subgroups was not presented in the publication. The level of significance was set p ≤ 0.05.
Data collection and analysis
Selection of studies
Two review authors (KB, WH) independently scrutinized all the titles and abstracts and selected studies based on inclusion and exclusion criteria.
Data extraction and management
Two authors extracted data on the studies (including the methods, settings, participants, interventions, outcomes, results, funding, conflicts of interest) independently using a specially designed data extraction form (KB, WH). The classification of the psychological therapies was rated independently by two authors (KB, WH) based on the details of therapy as reported by the authors, on the classification of IPTs as outlined in TYPES OF INTERVENTION and on the classification of CBTs used in a review on traditional face-to-face CBTs for FMS (Bernardy et al., 2018) . Reported treatment quality was rated independently by two authors (KB, WH). We resolved disagreements by discussion, if necessary a third review author (PW) was consulted. One author (WH) entered data into Review Manager (RevMan) 5.3 (RevMan, 2014) , and a second author (KB) validated the entries.
Assessment of risk of bias in included studies
Two review authors (KB, WH) independently assessed the risk of bias of each trial included. Disagreements were resolved by discussion and consensus, otherwise a third review author (PW) acted as arbiter. We assessed the following risks of bias for each study in accordance with methods recommended by The Cochrane Collaboration (Higgins et al., 2017) . We excluded the option of 'blinding participants and personnel' because neither therapists nor patients can be blinded to whether they deliver or receive treatment (Williams et al., 2012) . We did not consider small sample size bias because this approach would disadvantage trials with psychological therapies with no or public funding (allowing only small to moderate sample sizes) against drug trials sponsored by the manufacturers of the drugs. The details of the assessment of the risks of bias are outlined in Supporting Information Methods S2. We defined studies with 0-2 unclear or high risks of bias to be high quality studies, with 3-4 unclear or high risks of bias to be moderate quality studies, and with 5-6 unclear or high risks of bias to be low-quality studies (H€ auser et al., 2015b).
Assessment of quality of treatment
We assessed the quality of the treatment using five criteria (treatment content and setting, treatment duration, manualization of the treatment, adherence of the therapist to the manual, therapist training and client engagement) on a quality rating scale designed specifically for application to psychological treatment studies in pain. For client engagement, we required that engagement of patients was sought by checks if homework were made. The total score ranges from 0 to 9 (Yates et al., 2005) . We considered scores 0 to 2 to indicate poor quality, scores 3 to 5 average, and scores 6 to 9 excellent treatment quality (Bernardy et al., 2018) .
Unit of analysis issues
See Supporting Information Methods S3.
Dealing with missing data
Assessment of heterogeneity
Assessment of publication bias
Grading of evidence
The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach (Guyatt et al., 2011) was employed to interpret the quality of evidence. GRADE approach defines the quality of the evidence as the extent of confidence in the estimates of treatment benefits and their safety.
For details see Supporting Information Methods S3.
Results
Search
The search produced 430 hits. We excluded one study because it included patients with chronic widespread pain with and without FMS and did not present the data for FMS-patients separately (Kristj ansd ottir et al., 2013). We excluded one study which was not based on an established psychological framework to our opinion (Brattberg, 2008) . We inluced six studies (Williams et al., 2010; Davis and Zautra, 2013; Friesen et al., 2017; Menga et al., 2014; Vallejo et al., 2015; Hedman-Lagerl€ of et al., 2018) with seven study arms into the qualitative and quantitative analysis (see Fig. 1 ).
Included studies
The main characteristics of the studies are summarized in Table 1, for details see Supporting Information Table S1 .
Settings
Three studies were conducted in the USA (Williams et al., 2010; Davis and Zautra, 2013; Menga et al., 2014) , two studies in Europe (Sweden: HedmanLagerl€ of et al., 2018; Spain: Vallejo et al., 2015) and one in Canada (Friesen et al., 2017) .
Types of psychological therapies
Three studies applied traditional CBT (Williams et al., 2010; Vallejo et al., 2015; Friesen et al., 2017) . One study used exposure-based CBT . One study applied acceptance-based CBT (Davis and Zautra, 2013) . One study used combined traditional CBT and interpersonal therapy (Menga et al., 2014) . We found no studies with online therapy. For details see Supporting Information Table S2 .
Study design
All studies used a parallel design.
Study duration ranged between 6 and 12 weeks. Three studies performed a follow-up, one study after 4 weeks (Friesen et al., 2017) and two studies after 6 and 12 months (Vallejo et al., 2015; HedmanLagerl€ of et al., 2018) . The follow-up was only presented for the intervention group.
The number of lessons ranged between 5 and 13. Three studies included a contact with a psychotherapist (Vallejo et al., 2015; Friesen et al., 2017; Hedman-Lagerl€ of et al., 2018) . Three studies were unguided (Williams et al., 2010; Davis and Zautra, 2013; Menga et al., 2014) .
Controls
One study used attention controls (Davis et al., 2013) and one study used standard care (Williams et al., 2010) . The remaining studies used waiting list control and standard care. One study had a third arm with face-to face traditional CBT (Vallejo et al., 2015) .
Participants
We included a total of 246 participants in treatment groups and 247 participants in control groups in the analysis. The number of participants in psychological therapy and control groups each ranged from 20 to 70. Participants were recruited by media by all studies. In addition, participants were referred by physicians (general practitioners, rheumatologists) in three studies (Williams et al., 2010; Menga et al., 2014; Vallejo et al., 2015) .
The percentage of women in the studies rangend between 95% and 100%. All studies included only adults. If reported, the mean age of the participants ranged between 46 and 59 years. Four studies reported on the duration of chronic widespread pain or time since FMS-diagnosis which ranged between 8 and 12 years (Williams et al., 2010; Vallejo et al., 2015; Friesen et al., 2017; Hedman-Lagerl€ of et al., 2018) . 
Diagnosis of FMS
FMS was diagnosed in three studies by American College of Rheumatology (ACR) 1990 classification criteria (Wolfe et al., 1990; Menga et al., 2014; Vallejo et al., 2015; Williams et al., 2010) . The remaining studies relied on the reports of the participants that the diagnosis of FMS was established by a physician.
Exclusion of anxiety or depressive disorder
Two studies used a standardized psychiatric interview at study entry (Davis and Zautra, 2013; HedmanLagerl€ of et al., 2018) and two studies a non-standardized interview (Vallejo et al., 2015; Friesen et al., 2017) . One study used a standardized questionnaire for mental disorders (Williams et al., 2010) . One study did not report on a psychiatric assessment (Menga et al., 2014) . One study excluded patients with more than five episodes of depression (Davis and Zautra, 2013) . Two studies excluded patients with severe mental disorder (Williams et al., 2010; Menga et al., 2014) . One study excluded patients with severe depression (Hedman-Lagerl€ of et al., 2018).
Reported treatment quality
The reported treatment quality of all studies was high (see Section 3).
Funding and conflicts of interest
All studies but one (Menga et al., 2014) received public funding. All authors reported that they have no conflict of interest.
Risk of bias in included studies
According to the predefined categories, three studies were high-quality studies (low risk of bias overall) (Williams et al., 2010; Davis and Zautra, 2013 ; Hedman-Lagerl€ of et al., 2018), two studies were moderate quality studies (unclear risk of bias overall) (Vallejo et al., 2015; Friesen et al., 2017) and one study was a low-quality study (high risk of bias overall) (Menga et al., 2014 ; see Fig. 2 for risk of bias graph and Supporting Information Table S4 for details). Disability: We entered four studies with 358 participants into an analysis of reduction of disability. ICBTs were statistically significantly superior to controls (p-value 0.01; I 2 74). SMD was À0.56 (95% CI À1.00 to À0.13). According to the predefined categories, the effect size was moderate and there was a clinically relevant benefit by ICBTs. The quality of evidence was moderate, downgraded by one level because of inconsistency (large CI).
Effects of intervention
Negative mood: We entered five studies with 437 participants into an analysis of reduction of negative mood. ICBTs were statistically significantly superior to controls (p-value 0.005; I 2 69). SMD was À0.51 (95% CI À0.87 to À0.15). According to the predefined categories, the effect size was medium and there was a clinically relevant benefit by ICBTs. The quality of evidence was moderate, downgraded by one level because of inconsistency (large CI). Acceptability: We entered six studies with 493 participants into an analysis of acceptability. There was no statistically significant difference between ICBTs and controls (p-value 0.52; I 2 67%). Sixteen out of 246 (6.5%) participants in ICBTs groups and 9 out of 247 (3.6%) in the control group dropped out of the study due to any reason. RD was 0.02 (95% CI À0.03 to 0.07). The quality of evidence was high.
Safety: No study reported on safety. The quality of evidence was very low.
3.4.1.2 Secondary outcomes. Pain relief of 30% or greater: Three studies (Williams et al., 2010; Vallejo et al., 2015; Friesen et al., 2017) reported this outcome. We calculated this outcome for Davis and Zautra (2013) and Hedman-Lagerl€ of et al. (2018) . We entered five studies with 437 participants into an analysis of pain relief of 30% or greater. There was no statistically significant difference between ICBTs and controls (p-value 0.06; I 2 82). Sixty-seven out of 218 (30.7%) participants in ICBTs groups and 29 out of 219 (13.2%) in control groups reported pain relief of 30% or greater. RD was 0.14 (95% CI 0.01 to 0.28). The quality of evidence was moderate, downgraded by one level because of inconsistency (I 2 ≥ 75).
Improvement of health-related quality of life of 20% or greater: No study reported this outcome. The numbers of the reporting studies were calculated by an imputation method. We entered four studies with 284 participants into an analysis of improvement of health-related quality of life of 20% or greater. ICBTs were statistically significantly superior to controls (p-value 0.001; I 2 28%). Seventy out of 137 (51.1%) participants in ICBTs groups and 40 out of 147 (27.2%) participants in control groups reported improvement of health-related quality of life of 20% or greater. RD was 0.22 (95% CI 0.09 to 0.35). NNTB was 4 (95% CI 3 to 11). According to the predefined categories, there was a clinically relevant benefit by ICBTs. The quality of evidence was downgraded by one level to moderate because of imprecision (<400 participants in analysis).
Coping with pain: We entered four studies with 319 participants into an analysis of improved coping with pain. ICBTs were statistically significant superior to controls (p-value <0.0001; I 2 27%). SMD was À0.64 (95% CI À0.91 to À0.36). According to the predefined categories, the effect size was medium and there was a clinically relevant benefit by ICBTs. The quality of evidence was downgraded by one level to moderate because of imprecision (<400 participants). Fatigue: We entered four studies with 358 participants into an analysis of the reduction of fatigue. ICBTs were not statistically significant superior to controls (p-value 0.05; I 2 73). SMD was À0.42 (95% CI À0.85 to 0.01). The quality of evidence was downgraded by two levels to low because of inconsistency (large CI) and imprecision (<400 participants).
Sleep problems: We entered three studies with 318 participants into an analysis of the reduction of sleep problems. ICBTs were statistically significant superior to controls (p-value 0.006; I 2 0). SMD was À0.31 (95% CI À0.53 to À0.09). According to the predefined categories, the effect size was small and there was a clinically relevant benefit by ICBTs. The quality of evidence was downgraded by two levels to low because of inconsistency (large CI) and imprecision (<400 participants).
For Forest Plots see Supporting Information Figure S1 .
CBTs versus controls (waiting list, treatment as usual, attention at long-term follow up
We report qualitatively the results at 6-month follow-up of the ICBTs groups:
Hedman-Lagerl€ of et al. (2018) reported statistically significant small intragroup effect sizes for disability and fatigue and moderate intragroup effect sizes for pain, negative mood, health-related quality of life and coping with pain at 6-month follow-up. Vallejo et al. (2015) reported statistically significant small intragroup effect sizes for health-related quality of life and large intragroup effects for coping with pain.
ICBTs versus traditional face to face therapies
Vallejo et al. compared traditional ICBT with traditional face-to-face CBT using the same lessons with 20 patients each. At the end of treatment, no statistically significant between-group differences were found for mean pain intensity, physical functioning, HRQoL, coping with pain and fatigue. ICBT was statistically significant superior to traditional face-toface CBT for negative mood (p < 0.001). At 6-month follow-up, no statistically significant between-group differences were found for mean pain intensity, and fatigue. ICBT was statistically significant superior to traditional face-to-face CBT for disability, negative mood, HRQoL and coping with pain (all p < 0.001).
Heterogeneity
There was considerable heterogeneity (I 2 > 75%) in the comparisons pain relief of 50% or greater and 30% or greater at the end of treatment.
Publication bias
Studies with 426 participants with a null effect on improvement of health-related quality of life of 20% or greater would have been required to make the result clinically irrelevant (NNTB of 10 or higher).
Subgroup analyses: guided versus unguided ICBTs
Analysed with at least two studies available per subgroup were possible for these outcomes: We did not find a statistically significant difference in pain relief of 50% or greater (p value 0.18), acceptability (p value 0.52) and pain relief of 30% or greater (p value 0.06): Guided ICBTs were statistically significant superior to unguided therapies for reducing negative mood (p value 0.005).
Discussion
Summary of main results
ICBTs were superior to controls (waiting list, attention control, treatment as usual) in reducing negative mood and disability (medium effect sizes; moderate quality evidence) and sleep problems (small effect size; low-quality evidence) and in improving of health-related quality of life of 20% or greater (NNTB 4; moderate quality evidence) and coping with pain (medium effect size; moderate quality evidence) at the end of treatment. ICBTs and controls did not differ in pain relief of 50% (and 30%) or greater, in improving coping with pain and in acceptability (all moderate effect size) at the end of treatment.
Subgroup analyses demonstrated that guided ICBTs were superior to unguided CBTs in reducing negative mood, but not in pain relief of 50% (and 30%) or greater and in acceptability.
The comparisons of one study which compared traditional face-to-face CBT with guided traditional CBT came to mixed results.
Overall completeness and applicability of evidence
We cannot rule out the possibility that negative study results with psychological therapies had not been published or had been missed by our search strategy.
The applicability (external validity) of evidence is strong for the following reasons.
(1) The studies included patients of all levels of care.
(2) Patients with slight and moderate anxiety or depressive disorder, or both, which are frequently associated with FMS, were included in most studies. (3) The majoirity of the studies did not exclude patients with inflammatory rheumatic diseases.
However, the majority of the participants were middle-aged Caucasian women, making it difficult to apply the results to the total FMS population, especially to male and non-Caucasian patients. No study performed a subgroup analysis for male and nonCaucasian patients. However, the gender composition of the included studies does reflects the gender imbalance in this condition. In addition, the diagnosis of FMS was based for the majority on self-reports of the patients that the diagnosis has been established by a physician. 86% of patients with a self-report of a physician established diagnosis of FMS in the German fibromyalgia survey (H€ auser et al., 2012 ) met the 2011 criteria, but only 26% in the 2012 National Health Interview Survey (Walitt et al., 2016) .
Potential biases in the review process
We might have underestimated the methodological and treatment quality of some studies which might not have reported some details required for the risk of bias and treatment quality scores used. We relied on the reported data for quality assessment and did not ask authors for further details because we did not want to introduce a 'response' bias.
One author (Menga et al., 2014) did not provide outcomes which were assessed but not reported in the publication on request.
No study reviewed assessed adverse events.
Agreements with other reviews and randomized controlled trials
Some of our results are in line with a recent systematic review on traditional face-to-face CBTs (Bernardy et al., 2018) : Both ICBTs and traditional faceto-face CBTs reduce negative mood and disability (small effect sizes) and improve HRQoL and coping with pain (moderate effect size) if compared to 'traditional' control groups of psychological therapies (attention control, treatment as usual, waiting list) at the end of treatment. The positive results of ICBTs can be maintained at 6 months. Some of our results concur with the ones of the systematic reviews on Internet-delivered psychological therapies for chronic pain in adults (Eccleston et al., 2014; Buhrman et al., 2016) : For non-headache conditions, psychological therapies delivered via the Internet-reduced disability. We could not confirm the results on the reduction of pain intensity.
Guided ICBTs are in general superior to unguided interventions regarding the reduction of symptom severity in a range of mental disorders (Carlbring et al., 2018) . A recently published randomized controlled trial found that online acceptance and commitment therapy combined with treatment as usual was superior to treatment as usual in reducing fibromyalgia impact and depression (Simister et al., 2018) . For (mixed) chronic pain patients a recent randomized controlled study also showed that guided ICBT (Acceptance and Committment therapy was significantly more effective in reducing pain interference than the control group (waiting list) and was superior to the unguided group (Lin et al., 2017) . The finding that guidance is a crucial point in ICBTs was endorsed for negative mood in our study, but not for pain intensity.
Conclusions
Implications for clinical practice
ICBTs could be particularly useful in a graduated approach, where mild to moderately affected patients can be offered ICBTs by their general practitioner, or rheumatologists, thus freeing resources for patients with severe FMS to be treated in specialized settings . Logistic barriers are also eliminated, as patients receiving ICBTs do not have to travel once a week to receive the treatment. This makes ICBTs particularly promising in more rural areas of first world countries and in second and third world countries, where the access to trained therapists is limited.
Major tasks for future research
Some major tasks for future research which have been outlined for traditional face-to-face CBTs are also valid for ICBTs such as
• The definition of subgroups with development of more tailored therapies to these subgroups (H€ auser et al., 2018); • The development of graduated treatment approaches (e.g. education, nonguided ICBTs, guided CBTs; multicomponent therapies) depending on the severity of FMS (H€ auser et al., 2018); • The identification of common (e.g. therapeutic relationship) and specific treatment mechanisms; the identification of predictors of a favourable outcome (Bernardy et al., 2018 );
• The assessment and prevention of (serious) adverse events such as mental health episodes (e.g. suicide attempts, mental health-related hospital admissions) during or immediately after therapy; clinically relevant deterioration at the end of treatment; very negative experience of the therapy by the patient (Parry et al., 2016) • The application of new study designs beyond the 'gold standard' of RCTs, e.g. clinical effectiveness trials (Bernardy et al., 2018) . Specific tasks for Internet-delivered psychological therapies are as follows (Berger, 2018 ):
• How much qualification of the e-coach is needed (student; licensed psychotherapist with and without specialized postgraduate training) ?
• How much personal contact with a MHCP is needed and cost-effective?
• How can therapeutic rapport be build over the Internet?
• How can privacy protection be ensured?
• How do respond on crisis, e.g. suicidal ideation?
• How can ICBTs be dissiminated and implemented in routine clinical care?.
The completion of these tasks could improve the relatively modest effect sizes and overcome the uncertainties about safety of ICBTs which we found in this review.
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